| Malignant neoplasm of breast
Halaven vs Verzenio
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Halaven vs Verzenio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVerzenio has a higher rate of injection site reactions vs Halaven based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Verzenio but not Halaven, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Halaven
Verzenio
At A Glance
IV infusion
Days 1 and 8 of a 21-day cycle
Microtubule dynamics inhibitor
Oral
Twice daily
CDK4/6 inhibitor
Indications
- Malignant neoplasm of breast
- Sarcoma
- Malignant neoplasm of breast
- Carcinoma breast stage IV
Dosing
Malignant neoplasm of breast, Sarcoma 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle; reduce to 1.1 mg/m2 for mild hepatic impairment (Child-Pugh A) or moderate/severe renal impairment (CLcr 15-49 mL/min); reduce to 0.7 mg/m2 for moderate hepatic impairment (Child-Pugh B).
Malignant neoplasm of breast 150 mg orally twice daily in combination with tamoxifen or an aromatase inhibitor for 2 years as adjuvant treatment (or until disease recurrence or unacceptable toxicity).
Carcinoma breast stage IV 150 mg orally twice daily in combination with an aromatase inhibitor (initial therapy) or fulvestrant (after endocrine therapy progression); 200 mg orally twice daily as monotherapy (after endocrine therapy and prior chemotherapy); continue until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=25%) - Metastatic breast cancer Neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, constipation
Most common (>=25%) - Liposarcoma and leiomyosarcoma Fatigue, nausea, alopecia, constipation, peripheral neuropathy, abdominal pain, pyrexia
Serious Febrile neutropenia, neutropenia
Postmarketing Lymphopenia, pancreatitis, hepatotoxicity, drug hypersensitivity, pneumonia, sepsis/neutropenic sepsis, interstitial lung disease, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=20%) diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, thrombocytopenia
Serious neutropenia, diarrhea, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism
Postmarketing interstitial lung disease/pneumonitis
Pharmacology
Eribulin mesylate is a microtubule dynamics inhibitor that inhibits the growth phase of microtubules, sequesters tubulin into nonproductive aggregates, and exerts antimitotic effects via G2/M cell-cycle block and disruption of mitotic spindles, ultimately leading to apoptotic cell death after prolonged mitotic blockage.
Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); in ER-positive breast cancer cells, it blocks Rb phosphorylation and cell cycle progression from G1 into S phase, resulting in senescence and apoptosis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Halaven
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Verzenio
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Halaven
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Verzenio
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Halaven
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Verzenio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HalavenView full Halaven profile
VerzenioView full Verzenio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.